Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ambroxol reverses tau and α-synuclein accumulation in a cholinergic N370S GBA1 mutation model.

Human molecular genetics - 21 Jul 2022

Yang Shi Yu, Taanman Jan-Willem, Gegg Matthew, Schapira Anthony H V

Abstract excerpt

Cognitive impairment is a common non-motor complication of Parkinson's disease (PD). Glucocerebrosidase gene (GBA1) variants are found in 10-15% of PD cases and are numerically the most important risk factor for PD and dementia with Lewy bodies. Accumulation of α-synuclein and tau pathology is thought to underlie cognitive impairment in PD and likely involves cholinergic as well as dopaminergic neurons. Neural...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to alpha-Synuclein
Share to Cathepsin D
Share to Cells, Cultured

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glucosylceramidase

Share to Mutation

Share to Parkinson Disease

Share to tau Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 35179198
DOI: 10.1093/hmg/ddac038
PMCID: PMC9307316

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ambroxol reverses tau and α-synuclein accumulation in a cholinergic N370S GBA1 mutation model.PMID 35179198Read ↗

A Human Neural Crest Stem Cell-Derived Dopaminergic Neuronal Model Recapitulates Biochemical Abnormalities in GBA1 Mutation Carriers.Semantic proximity Read ↗

Enhancing the Activity of Glucocerebrosidase as a Treatment for Parkinson Disease.Semantic proximity Read ↗

Glucocerebrosidase as a therapeutic target for Parkinson's disease.Semantic proximity Read ↗

Glucocerebrosidase and Parkinson Disease: Molecular, Clinical, and Therapeutic Implications.Semantic proximity Read ↗

Cross-talks among GBA mutations, glucocerebrosidase, and α-synuclein in GBA-associated Parkinson's disease and their targeted therapeutic approaches: a comprehensive review.Semantic proximity Read ↗

GBA Variants and Parkinson Disease: Mechanisms and Treatments.Semantic proximity Read ↗

Glucocerebrosidase mutations and Parkinson disease.Semantic proximity Read ↗

The interplay between Glucocerebrosidase, α-synuclein and lipids in human models of Parkinson’s diseaseSemantic proximity Read ↗

Advances in GBA-associated Parkinson's disease--Pathology, presentation and therapies.Semantic proximity Read ↗

Gene Therapy for Parkinson's Disease Associated with GBA1 Mutations.Semantic proximity Read ↗

Glucocerebrosidase mutations and synucleinopathies: Toward a model of precision medicineSemantic proximity Read ↗

GBA1-Associated Parkinson's Disease Is a Distinct Entity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.